At the Advances in Neuroblastoma Research (ANR) 2025 conference, the Institut Curie and its SIREDO center presented promising results concerning neuroblastoma, a pediatric cancer that is particularly complex to treat. The work was led by Dr. G. Schleiermacher, pediatrician and deputy director of translational research at the SIREDO center, and I. Janoueix-Lerosey, Inserm research director and team leader at the Institut Curie.

Research focuses on three main areas. On the one hand, the team is developing new therapeutic strategies for low-risk neuroblastoma as part of the SIOPENS-LINE study. Secondly, it is working on improving relapse prevention in high-risk neuroblastoma by analyzing circulating biomarkers, a project being conducted as part of the MICCHADO study. Finally, researchers are working to better understand the development of neuroblastoma in order to develop future new treatments.